XmAb657

Multispecific antibody

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Idiopathic Inflammatory Myopathies

Competitive landscape

3 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for Idiopathic Inflammatory Myopathies: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
XmAb657: this drugPhase 1Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
Blinatumomab
Approved(overall)
Multispecific antibodyCD19 x CD3
Partial signal(overall)
No reviewed efficacy summary in this indication
Brepocitinib (Lisraya)ApprovedSmall moleculeTYK2/JAK1not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
AnifrolumabPhase 3Monoclonal antibodyType I interferon receptor subunit 1 (IFNAR1)not yet gradedNo reviewed efficacy summary in this indication
Surovatamig
Phase 3(overall)
Multispecific antibodyCD19 x CD3
not yet graded(overall)
No reviewed efficacy summary in this indication
CLN-978
Phase 1(overall)
Multispecific antibodyCD19 x CD3
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow XmAb657 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
October 2028 (1)
Phase 1Idiopathic Inflammatory MyopathiesRecruiting
Est. primary completion 2028-10 · NCT07284797 · CT.gov ↗
What to watch

See the full readout calendar ↗